key: cord-0890761-yver4stw
authors: Hosoda, Tomohiro; Hamada, Shota; Numata, Kenji; Saito, Yutaka; Yamazaki, Satsuki; Minoura, Ayu; Sakamoto, Mitsuo; Fujitani, Shigeki
title: Intensive care burden of COVID-19 in tertiary care hospitals during the first year of outbreak in Kawasaki City, Japan: A retrospective cohort study
date: 2022-02-09
journal: J Infect Chemother
DOI: 10.1016/j.jiac.2022.01.022
sha: ac40651aa27635d0ebe2e69990ca5f88ebdbefaf
doc_id: 890761
cord_uid: yver4stw

INTRODUCTION: This study aimed to describe the changes in the intensive care burden of coronavirus disease 2019 (COVID-19) during the first year of outbreak in Japan. METHODS: This retrospective cohort study included COVID-19 patients who received mechanical ventilation (MV) supportsupport in two designated hospitals for critical patients in Kawasaki City. We evaluated the lengths of MV and stay in the intensive care unit (ICU) or high care unit (HCU) during the three epidemic waves. We calculated in-hospital mortality rates in patients with or without MV. RESULTS: The median age of the sample was 65.0 years, and 22.7% were women. There were 37, 29, and 62 patients in the first (W1), second (W2), and third waves (W3), respectively. Systemic steroids, remdesivir, and prone positioning were more frequent in W2 and W3. The median length of MV decreased from 18.0 days in W1 to 13.0 days in W3 (P = 0.019), and that of ICU/HCU stay decreased from 22.0 days in W1 to 15.5 days in W3 (P = 0.027). The peak daily number of patients receiving MV supportsupport was higher at 18 patients in W1, compared to 8 and 15 patients in W2 and W3, respectively. The mortality rate was 23.4%, which did not significantly change (P = 0.467). CONCLUSIONS: The lengths of MV and ICU/HCU stay per patient decreased over time. Despite an increase in the number of COVID-19 patients who received MV in W3, this study may indicate that the intensive care burden during the study period did not substantially increase.

Since the identification of the first coronavirus disease 2019 (COVID-19) patient in January 2020, approximately 1.7 million patients in Japan had a confirmed diagnosis of COVID-19, with >17,000 estimated deaths by the end of September 2021 [1] . Fortunately, the number of patients and deaths due to COVID-19 remains smaller in Japan than in most Western countries [2] . However, despite the accumulation of knowledge and experience in infection control for COVID-19, intermittent epidemics continue to occur worldwide, including in Japan [3] .

Some COVID-19 patients experience rapid deterioration and require intensive care unit (ICU) treatment and long-term mechanical ventilation support during the clinical course [4, 5] . As the number of COVID-19 patients increased, several countries, such as Italy and Brazil, faced a shortage of intensive care resources, including ICU beds and mechanical ventilators, during the early epidemic phase [6, 7] . Increasing pressure on critical care capacity was associated with a greater risk of ICU mortality among COVID-19 patients [8] , which had been similarly noted in other diseases, such as respiratory and heart diseases [9] . In the US and UK, where a serious outbreak of COVID-19 occurred in the early epidemic phase, reductions in in-hospital mortality among COVID-19 patients were noted following changes in hospital strategy and clinical processes based on J o u r n a l P r e -p r o o f accumulated experience and knowledge and the introduction of effective medications evidenced by randomized controlled trials, during the first several months of the COVID-19 epidemic [10, 11] .

In Japan, most critically ill patients with COVID-19, especially those who required mechanical ventilation support, have been referred to tertiary care hospitals designated for critical COVID-19 treatment by local governments to efficiently utilize the workforce of trained staff and medical resources (e.g., personal protective equipment and mechanical ventilation machines). Strain in intensive care at these designated tertiary care hospitals could directly increase the risk of mortality and lead to poor prognosis among COVID-19 patients in the entire district. Although intensive care resource use, including the lengths of ICU stay and mechanical ventilation support, has been investigated in Japan [12] [13] [14] , there is limited knowledge on the changes in intensive care use per patient and in intensive care burden on a district over time due to COVID-19.

Therefore, this study aimed to describe the changes in the intensive care burden of critical COVID-19 patients at the two tertiary care hospitals designated for critical COVID-19 treatment in Kawasaki City during the first year of the COVID-19 outbreak in Japan.

J o u r n a l P r e -p r o o f

Kawasaki City is located between Tokyo and Yokohama City in Japan, with approximately 1.4 million people. There are two secondary medical areas in the city: the northern and southern areas covered approximately 840,000 and 630,000 people, respectively, based on data for 2015. According to the public health center in Kawasaki City, three major waves occurred during the first year of the COVID-19 outbreak. The highest number of COVID-19 patients identified per week was 71 in early April 2020 (first wave), 151 in late July 2020 (second wave), and 1,148 in late December 2020 (third wave) [15] . At the end of February 2021, more than 8,000 COVID-19 patients had been confirmed, including 132 deaths [15] . This retrospective cohort study was conducted in two tertiary care hospitals (i.e., The numbers of COVID-19 patients hospitalized in all designated hospitals in Kawasaki City, regardless of those with or without mechanical ventilation support, were shared every day among all designated hospitals for COVID-19 patients, including the two study facilities for critical patients throughout the study period. Therefore, we confirmed that all COVID-19 patients with mechanical ventilation support in the city were hospitalized in either of the two study facilities.

The first patients with COVID-19 were admitted to these hospitals in March 2020. The study participants included COVID-19 patients aged ≥15 years who were hospitalized between March 2020 and February 2021 and received mechanical ventilation during hospitalization. We limited our study to patients with mechanical ventilation support, not all patients who stayed in ICU/HCU, in order to exclude patients with non-critical COVID-19 but admitted to ICU/HCU. The study participants were followed up until May 31, 2021. As referenced, we also investigated patients J o u r n a l P r e -p r o o f mechanical ventilation support.

The outcome measures were the lengths of mechanical ventilation and ICU/HCU stay, which were defined as the cumulative days during hospitalization. Thus, for example, when a patient is readmitted to ICU/HCU after discharge from ICU/HCU, we summed up the lengths of each ICU/HCU stay during hospitalization.

Data were collected through a retrospective chart review and included the following: demographics, comorbidities, date of onset, date of laboratory diagnosis, date of admission to the study facilities, date of discharge or transfer to another hospital, the severity of COVID-19 at admission, treatment of COVID-19, including pharmacotherapy, the use of extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy, and all-cause in-hospital mortality. Moreover, the mortality rates in patients with or without mechanical ventilation support were evaluated following the changes in decision making when performing mechanical J o u r n a l P r e -p r o o f ventilation support over time might affect the mortality rate in patients who did not receive mechanical ventilation support during the study period.

COVID-19 was diagnosed if they had both of close contact history with COVID-19 patients or typical clinical symptoms and at least one of the following laboratory evidence: polymerase chain reaction testing, quantitative or qualitative antigen testing, or serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 severity was classified according to the classification published by the US National Institutes of Health: asymptomatic; mild (any of the various signs and symptoms without shortness of breath, dyspnea, or abnormal chest imaging); moderate (evidence of lower respiratory disease with oxygen saturation (SpO2) ≥94% on room air at sea level), severe (SpO2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg, respiratory frequency >30 breaths/min, or lung infiltrates >50%), and critical (respiratory failure, septic shock, and/or multiple organ dysfunction) [16] . The severity of patients who required mechanical ventilation support for respiratory failure due to COVID-19 but did not receive mechanical ventilation support due to unavailability of consent for the procedure was defined as critical in this study. ICU beds were defined as deploying with a nurse-patient ratio of 1:2 and HCU beds as deploying with a nurse-patient ratio of 1:4.

According to the epidemic curve of COVID-19 in Japan, the study period was divided into three equal terms: the first wave (March 2020 to June 2020), the second wave (July 2020 to October 2020), and the third wave (November 2020 to February 2021). The study patients were then divided into three groups corresponding to each wave based on admission to the study facilities.

Characteristics of the study patients were compared according to waves using Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables, with the Dunn-Bonferroni post hoc method for two-group comparisons. As a sensitivity analysis, the analyses were repeated only in surviving patients at discharge. SPSS (version 25.0.0, Inc., Chicago, IL, USA) was used to analyze the data, and statistical significance was set at P < 0.05.

This study was conducted in compliance with the standards of the Declaration of 

Among the 505 COVID-19 patients who were admitted to the study facilities during the study period, 128 patients who received mechanical ventilation support during hospitalization were included. The median age of the study population was 65.0 years, and 22.7% were women ( Table 1) (Table S1 ).

The proportion of patients administered with antibiotics on admission in the third wave was lower than those in the first and second waves (Table 2) 

The all-cause mortality rate during hospitalization was 23.4% (n = 30), which did not significantly change during the study period (P = 0.467) ( Table 2) 

Sensitivity analysis was conducted in 98 patients who received mechanical ventilation support for COVID-19 treatment and survived at discharge (Table S2 ). The length of mechanical ventilation decreased over time, with a median of 18.0 days, 14.0 days, and 13.0 days in the first, second, and third waves, respectively (P = 0.041, Figure   S1a ). The length of ICU/HCU stay decreased over time, with a median of 21.0 days, 16 .0 days, and 14.5 days in the first, second, and third waves, respectively (P = 0.058, Figure S1b ). These results were similar to those obtained from the main analysis.

We found that the lengths of mechanical ventilation and ICU/HCU stay of critical ventilation and ICU stay, in the early epidemic phase in Japan [12] [13] [14] . A more recent study showed that the number of ICU patients peaked in the first wave in Osaka prefecture, which was consistent with our study [17] . Our results may also suggest that the intensive care burden due to an emerging infectious disease like COVID-19 should be predicted based on the latest data because resource use may be dynamically changed partly because of the accumulation of experience and evidence during the early epidemic phase.

One of the strengths of this study was the inclusion of virtually all critical COVID-19 patients with mechanical ventilation support in Kawasaki City; thus, this enabled us to evaluate the intensive care burden in the city. Approximately one-third of the study patients were residents outside the city, suggesting that the two hospitals had enough capacity to accept at least the most critical COVID-19 patients in the city. However, we acknowledge that some Kawasaki City residents with critical COVID-19 might have been admitted to hospitals outside the city.

According to the nationwide inpatient registry in Japan, the median lengths of mechanical ventilation and ICU stay among patients who received mechanical ventilation were 11 days and 13 days, respectively [18] , which were both shorter than those found in this study. These differences may be attributed to the difference in the initiation or termination criteria for mechanical ventilation in each study facility. For example, during the first wave, we avoided using a reservoir mask and high-flow nasal cannula for oxygenation because of concern for aerosol transmission but initiated mechanical ventilation in patients whose SpO2 levels remained lower than 90% even after the administration of 5 L/min oxygen through the oxygen mask. However, after the accumulation of evidence on the safety of reservoir masks and high-flow nasal cannula devices for COVID-19 patients [19] , we changed our practice to place these modalities ahead of mechanical ventilation support in the second to third waves. Thus, earlier application of mechanical ventilation in our hospitals during the first wave may prolong the lengths of mechanical ventilation and ICU/HCU stay, compared to those reported from the registry study. We speculate that the observed decrease in the lengths of mechanical ventilation and ICU/HCU stay during the study period may partly be due to substantial changes implemented in clinical practice and treatment protocol for critical COVID-19 patients during the study period [20] . For example, remdesivir (approved since May 2020 in Japan) and dexamethasone (July 2020) could improve the prognosis of COVID-19 patients [21, 22] . Furthermore, prone positioning during mechanical ventilation was proactively implemented in the hospitals during the second and third waves, which could have improved oxygenation [23] . Therefore, we considered that these medications and patient management, including deciding the appropriate timing of initiation or discontinuation of mechanical ventilation by the accumulation of intensive care experience for COVID-19, might have contributed to the shortened lengths of mechanical ventilation and ICU/HCU stay observed between the first and second waves.

It is important to note that the crude mortality rates of study patients with mechanical ventilation and those without remained low and did not significantly increase over the study period. This may be indicative of the absence of strain in intensive care in the study facilities and in the district over the study period. Moreover, we speculated that the selection of patients for mechanical ventilation might be performed appropriately because of no apparent increase in crude mortality rates among those without mechanical ventilation. However, further research with larger sample sizes is needed to verify this finding because we could not conduct analyses with adjustment for potential confounding factors due to the limited number of study participants. Furthermore, the continuous use of mechanical ventilation until death among patients who died after 28 days from J o u r n a l P r e -p r o o f admission may suggest that physicians did not stop their treatment due to a shortage of mechanical ventilation.

This study had two major limitations. Firstly, we could not compare the outcomes after adjustment for demographic and clinical characteristics of the patients because of the small sample size. Secondly, other factors, such as viral genomic variation, which may influence disease severity, may have affected the results of this study [24] . Further studies are required to determine the reasons for the observed changes in the lengths of mechanical ventilation and ICU/HCU stay. 

Ministry of Health, Labor and Welfare. Current status of new coronavirus infection and response by the Ministry of Health, Labor and Welfare

Hospital capacity during the COVID-19 pandemic

Survey of Critically ill COVID-19 patients in Japan

Severe Covid-19

Clinical characteristics, treatment, and outcomes of critically ill patients with COVID-19: A scoping review

At the epicenter of the Covid-19 pandemic and humanitarian crises in Italy: Changing perspectives on preparation and mitigation. NEJM Catal Innov Care Deliv

Covid-19: Brazil's hospitals close to collapse as cases reach record high

Association of Intensive Care Unit patient load and demand with mortality rates in US

Association between strained capacity and mortality among patients admitted to intensive care: A path-analysis modeling strategy

Emory COVID-19 Quality and Clinical Research Collaborative. Declines in mortality over time for critically ill adults with coronavirus Disease 2019

Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: An observational study using administrative data

The characteristics and clinical course of patients with COVID-19 who received invasive mechanical ventilation in Osaka, Japan

Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: A single-center observational study from the first wave

Critically ill patients with COVID-19 in Tokyo, Japan: A single-center case series

New coronavirus infectious disease outbreak status data

Clinical spectrum of SARS-CoV-2 infection

Characteristics and Survival of Intensive Care Unit Patients with Coronavirus Disease in Osaka, Japan: A Retrospective Observational Study

Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan

High-flow nasal cannula for COVID-19 patients: Low risk of bio-aerosol dispersion

Outcome improvement between the first two waves of the coronavirus disease 2019 pandemic in a single tertiary-care hospital in Belgium

Remdesivir treatment in hospitalized patients with COVID-19: A comparative J o u r n a l P r e -p r o o f analysis of in-hospital all-cause mortality in a large multi-center observational cohort

Dexamethasone in hospitalized patients with Covid-19

Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: Matched cohort study